Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?
Introduction
The benzodiazepines comprise a large group of drugs which are used extensively in psychiatry, neurology and other branches of medicine. They were first introduced over 30 years ago, and have been extensively prescribed to treat anxiety, insomnia, muscle spasm, and epilepsy. They have also been used to induce anaesthesia. Although generally regarded as safe and effective drugs, their risk/benefit profile is becoming increasingly questioned (Rosenbaum, 1982, Maczaj, 1993, Lader, 1994).
The benzodiazepines were originally marketed as improvements on the barbiturates and on meprobamate. They seemed much safer in overdose, had fewer drug interactions and probably a low liability for both dependence in licit medical use and illicit abuse ‘on the street’. Over the years the unwanted effects of the benzodiazepines have become more obvious: psychomotor/cognitive impairment is common and more serious neuropsychiatric reactions such as amnesic and aggressive episodes may occur. With long-term use dependence is now a recognised risk, and abuse, orally, intravenously and by ‘snorting’ (Sheehan et al., 1991) is a burgeoning worldwide concern. Despite these misgivings, the benzodiazepines are still regarded in many European countries as useful drugs providing they are prescribed appropriately. I will concentrate on two indications, anxiety and insomnia. Both tend to be chronic conditions.
Section snippets
Indications, dosage and duration of treatment
Fig. 1, Fig. 2 show the recommendations in the UK data sheets for diazepam and temazepam, respectively. Both refer to ‘short-term management’ when the disorder is “severe, disabling or subjecting the individual to extreme distress”. There are also similar definitions of ‘short-term’: 2–4 weeks which includes a tapering-off period in the case of temazepam. Extension beyond this time is acknowledged to be necessary sometimes but only with re-evaluation of the patient’s status.
Dosage
Short-term
Anxiety disorders are found commonly in the general population. Estimates range from 5 to 20% depending on the severity criteria for ‘caseness’ and the mode of detection. Generalised anxiety disorder is probably the commonest of these conditions, followed by panic disorder (with or without agoraphobia), and social phobia. Acute stress reactions and anxiety symptoms as part of other psychiatric disorders or physical disorders are very commonly encountered. Despite the frequency of these
Risks
These will be reviewed under several headings.
Other therapies
A range of other treatments are available, some being appropriate for long-term treatment. For GAD and PD, these alternatives include tricyclic antidepressants (TCAs) such as imipramine and clomipramine, selective serotonin reuptake inhibitors (SSRIs) like citalopram, fluoxetine, sertraline and paroxetine, and monoamine oxidase inhibitors (MAOIs) both non-selective and irreversible, like phenelzine, and selective and reversible (moclobemide). Such use of antidepressants is formally approved by
Conclusions
A wide spectrum of opinions is expressed concerning the benzodiazepines. As this symposium shows this ranges from protestations that they are valuable drugs grossly underused and therefore depriving suffering patients of effective symptomatic relief to judgements that their risk benefit ratios as anxiolytics and hypnotics is adverse under all circumstances. The middle ground, held by most prescribers is that short-term use is acceptable but that questions hang over long-term use.
Thus:
“even if
Summary
Benzodiazepines, despite their vicissitudes, are seen as effective treatments, at least in the short-term. The risk/benefit ratio of these drugs becomes less favourable or even adverse as treatment becomes prolonged: efficacy wanes and risks accumulate. Patients with severe anxiety, panic and insomnia disorders can be greatly helped by short-term intervention with a benzodiazepine but the benefits long-term remain debatable (Ashton, 1994, Lader, 1994). A comprehensive treatment strategy is
References (36)
Risk of traffic accident injury after a prescription for a benzodiazepine
Ann. Epidemiol.
(1995)- et al.
The Nottingham study of neurotic disorder: Comparison of drug and psychological treatments
Lancet
(1988) Guidelines for the rational use of benzodiazepines. When and what to use
Drugs
(1994)- et al.
Lorazepam in the elderly—A retrospective study of the side-effects in 20 patients
J. Psychopharmacol.
(1987) - et al.
Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial
Arch. Gen. Psychiatry
(1988) - et al.
Physiological and psychological measures in anxious patients
Psychol. Med.
(1974) Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis
Int. Clin. Psychopharmacol.
(1995)- et al.
Abuse of flunitrazepam (Rohypnol) and other benzodiazepines in Austin and South Texas
J. Psychoactive Drugs.
(1996) Benzodiazepines, memory and mood: A review
Psychopharmacology
(1991)- et al.
Long-term outcome of panic states during double-blind treatment and after withdrawal of alprazolam and placebo
Ann. Clin. Psychiatry
(1992)
Aggressive dyscontrol in patients treated with benzodiazepines
J. Clin. Psychiatry
Psychological treatment of generalised anxiety disorder. A review of the clinical significance of results in outcome studies since 1980
Br. J. Psychiatry
Untreated anxiety among adult primary care patients in a health maintenance organization
Arch. Gen. Psychiatry
Sleep laboratory studies of hypnotic drugs: Efficacy and withdrawal effects
J. Clin. Psychopharmacol
Benzodiazepines and vigilance performance: A review
Psychopharmacology
Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment
Arch. Fam. Med.
Rebound insomnia and newer hypnotics
Psychopharmacology
Cited by (206)
Barriers and enablers towards benzodiazepine-receptor agonists deprescribing in nursing homes: A qualitative study of stakeholder groups
2023, Exploratory Research in Clinical and Social PharmacyAn electrochemical sensor based on cobalt oxyhydroxide nanoflakes/reduced graphene oxide nanocomposite for detection of illicit drug-clonazepam
2022, Journal of Electroanalytical ChemistryHigh-throughput and trace analysis of diazepam in plasma using DART-MS/MS and its pharmacokinetic application
2021, Analytical BiochemistryCitation Excerpt :Diazepam (Fig. 1a) is an anxiolytic of the benzodiazepine family, which is commonly prescribed to treat the conditions of anxiety, sedative hypnotics, anticonvulsants and muscle relaxants [1–4].
Implementation of a digital cognitive behavioral therapy for insomnia pathway in primary care
2021, Contemporary Clinical TrialsThe effect of cognitive behavioural therapy for insomnia on sedative-hypnotic use: A narrative review
2021, Sleep Medicine ReviewsCitation Excerpt :Although melatonin administration is associated with fewer dependence/side-effects than BZDs and ‘z-drugs’, there is limited efficacy evidence to support melatonin in the management of insomnia [8,27,28]. Sedative-hypnotics are associated with cognitive, psychomotor, and medical side-effects [35,41–45], which place patients at increased risk of serious adverse events and outcomes, including falls and fractures [37,48], motor-vehicle accidents [49], health service use, hospital admissions [50,51], and mortality [52]. Furthermore, clinical guidelines commonly warn of the addictive potential of sedative-hypnotics, due to the rapid development of tolerance effects, and withdrawal symptoms experienced during dose reduction [8,27,28].